Spasmodic Dysphonia
25
4
5
13
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 25/100
4.0%
1 terminated out of 25 trials
92.9%
+6.3% vs benchmark
0%
0 trials in Phase 3/4
77%
10 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (25)
Zinc Supplementation Prior to Botox Injections for Spasmodic Dysphonia
Usability of Vibro-tactile Stimulation to Treat Spasmodic Dysphonia
Transcranial Magnetic Stimulation in Laryngeal Dystonia
DaxibotulinumtoxinA Injection for Treatment of Adductor Spasmodic Dysphonia
Extended-release Sodium Oxybate (Lumryz) in Spasmodic Dysphonia and Voice Tremor
Dysphonia Pain Perception Following Botulinum Toxin Injections
Sodium Oxybate in Spasmodic Dysphonia and Voice Tremor
Brain Networks in Dystonia
Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor
Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor
Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor
Spasmodic Dysphonia Interviews
Assessment of Laryngopharyngeal Sensation: Cancer Survivor Cohort
Laryngeal Vibration for Spasmodic Dysphonia
Spasmodic Dysphonia Pain
Assessment of Laryngopharyngeal Sensation in Adductor Spasmodic Dysphonia
Cortical Silent Period in Laryngeal Dystonia
A Phase 2 Trial of Deep Brain Stimulation for Spasmodic Dysphonia
Neuropathology of Spasmodic Dysphonia
Thalamic Deep Brain Stimulation for Spasmodic Dysphonia- DEBUSSY Trial